文献速递浆细胞疾病

硼替佐米在高剂量治疗前后用于骨髓瘤:III期HOVON-65/GMMG-HD4试验的长期结果

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.
PubMed 文献 · Leukemia · 2017-07-04

III期HOVON-65/GMMG-HD4试验比较硼替佐米联合方案(PAD组)与经典细胞毒药物联合沙利度胺方案(VAD组)在18-65岁多发性骨髓瘤患者中的疗效。中位随访96个月,PAD组无进展生存期显著延长(HR=0.76,95%CI 0.65-0.89,P=0.001),总生存期两组相似(HR=0.89,95%CI 0.74-1.08,P=0.24),第二原发肿瘤发生率两组均为7%(P=0.73)。

要点

  • 中位随访96个月,PAD组较VAD组无进展生存期显著延长(HR=0.76,95%CI 0.65-0.89,P=0.001)。
  • 总生存期两组相似(HR=0.89,95%CI 0.74-1.08,P=0.24)。
  • 第二原发肿瘤发生率两组均为7%(P=0.73)。

核心结论

  • 与经典细胞毒药物诱导和沙利度胺维持相比,硼替佐米诱导/维持治疗的生存获益得以维持,且未增加第二原发肿瘤风险。

研究设计与样本

  • III期HOVON-65/GMMG-HD4试验,纳入18-65岁多发性骨髓瘤患者,比较硼替佐米联合方案(PAD组)与经典细胞毒药物联合沙利度胺方案(VAD组)的长期随访及第二原发肿瘤数据。

主要发现

  • 中位随访96个月,PAD组较VAD组无进展生存期(删失于异基因移植)显著延长(HR=0.76,95%CI 0.65-0.89,P=0.001)。
  • PAD组与VAD组总生存期相似(HR=0.89,95%CI 0.74-1.08,P=0.24)。
  • PAD组与VAD组第二原发肿瘤发生率相似(各7%,P=0.73)。
  • 基线细胞遗传学异常del(17p13)(克隆大小≥10%)和肾功能损害(血清肌酐>2 mg dl-1)对PFS和OS的负向预后效应在PAD组中消失,但在VAD组中未消失。
  • 首次复发/进展后的总生存期两组相似(HR=1.02,P=0.85)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR)=0.76, 95% confidence interval (95% CI) of 0.65-0.89, P=0.001). Overall survival (OS) was similar in the PAD versus VAD arm (HR=0.89, 95% CI: 0.74-1.08, P=0.24). The incidence of SPM were similar between the two arms (7% each, P=0.73). The negative prognostic effects of the cytogenetic aberration deletion 17p13 (clone size ⩾10%) and renal impairment at baseline (serum creatinine >2 mg dl-1) on PFS and OS remained abrogated in the PAD but not VAD arm. OS from first relapse/progression was similar between the study arms (HR=1.02, P=0.85). In conclusion, the survival benefit with BTZ induction/maintenance compared with classical cytotoxic agents and thalidomide maintenance is maintained without an increased risk of SPM.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2017. PMID: 28761118. doi:10.1038/leu.2017.211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。